| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 14 | 2025 | 190 | 2.800 |
Why?
|
| B7-H1 Antigen | 20 | 2025 | 305 | 2.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 25 | 2025 | 1021 | 2.240 |
Why?
|
| NF-kappa B | 11 | 2016 | 469 | 1.610 |
Why?
|
| T-Lymphocytes | 15 | 2016 | 1316 | 1.550 |
Why?
|
| Albumins | 7 | 2021 | 135 | 1.140 |
Why?
|
| Paclitaxel | 8 | 2021 | 497 | 1.070 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2008 | 209 | 1.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 2642 | 0.980 |
Why?
|
| Graft Rejection | 10 | 2016 | 1126 | 0.890 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 553 | 0.830 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 555 | 0.760 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 225 | 0.760 |
Why?
|
| CARD Signaling Adaptor Proteins | 4 | 2012 | 15 | 0.730 |
Why?
|
| Antibodies, Monoclonal | 12 | 2019 | 1429 | 0.710 |
Why?
|
| Heart Transplantation | 6 | 2016 | 812 | 0.680 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2012 | 432 | 0.660 |
Why?
|
| Lymphocyte Activation | 11 | 2016 | 810 | 0.610 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 2418 | 0.600 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 801 | 0.590 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2014 | 350 | 0.550 |
Why?
|
| Biomarkers, Tumor | 11 | 2024 | 1670 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 1471 | 0.510 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 135 | 0.450 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 2061 | 0.450 |
Why?
|
| Cell Differentiation | 2 | 2012 | 1667 | 0.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2025 | 1172 | 0.420 |
Why?
|
| Interleukin-7 | 1 | 2014 | 47 | 0.420 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 42 | 0.410 |
Why?
|
| Skin Transplantation | 3 | 2016 | 193 | 0.410 |
Why?
|
| Bevacizumab | 4 | 2024 | 275 | 0.410 |
Why?
|
| Melanoma | 3 | 2019 | 497 | 0.410 |
Why?
|
| Signal Transduction | 9 | 2016 | 3581 | 0.410 |
Why?
|
| Mice, Inbred BALB C | 10 | 2016 | 1124 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 11 | 2016 | 3490 | 0.390 |
Why?
|
| Th17 Cells | 2 | 2014 | 97 | 0.380 |
Why?
|
| Genetic Variation | 1 | 2019 | 1423 | 0.380 |
Why?
|
| Transplantation | 1 | 2012 | 38 | 0.370 |
Why?
|
| Forkhead Transcription Factors | 2 | 2011 | 180 | 0.360 |
Why?
|
| Mice | 20 | 2023 | 12541 | 0.350 |
Why?
|
| Killer Cells, Natural | 3 | 2008 | 294 | 0.350 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 83 | 0.350 |
Why?
|
| Female | 34 | 2025 | 50046 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 319 | 0.340 |
Why?
|
| Humans | 53 | 2025 | 96114 | 0.340 |
Why?
|
| Dendritic Cells | 2 | 2012 | 541 | 0.340 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 307 | 0.330 |
Why?
|
| Middle Aged | 25 | 2025 | 28372 | 0.320 |
Why?
|
| Galectin 1 | 2 | 2011 | 6 | 0.310 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2016 | 218 | 0.310 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 2463 | 0.310 |
Why?
|
| Transplantation, Homologous | 8 | 2016 | 1023 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 5 | 2025 | 449 | 0.310 |
Why?
|
| Indoles | 2 | 2024 | 317 | 0.300 |
Why?
|
| Obesity | 1 | 2016 | 1034 | 0.300 |
Why?
|
| Mice, Transgenic | 6 | 2016 | 1645 | 0.300 |
Why?
|
| Caspases | 1 | 2009 | 156 | 0.290 |
Why?
|
| CD28 Antigens | 4 | 2011 | 94 | 0.290 |
Why?
|
| fas Receptor | 1 | 2009 | 76 | 0.290 |
Why?
|
| Animals | 22 | 2023 | 28919 | 0.290 |
Why?
|
| Cytokines | 4 | 2019 | 872 | 0.280 |
Why?
|
| CD3 Complex | 3 | 2011 | 136 | 0.280 |
Why?
|
| Thymus Gland | 1 | 2009 | 206 | 0.280 |
Why?
|
| STAT5 Transcription Factor | 3 | 2014 | 45 | 0.280 |
Why?
|
| Skin | 3 | 2019 | 605 | 0.280 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2004 | 126 | 0.280 |
Why?
|
| Langerhans Cells | 1 | 2007 | 17 | 0.270 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2004 | 34 | 0.270 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2004 | 38 | 0.270 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 46 | 0.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1346 | 0.270 |
Why?
|
| Cell Cycle | 1 | 2009 | 516 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 190 | 0.260 |
Why?
|
| Isoantigens | 3 | 2012 | 72 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 87 | 0.250 |
Why?
|
| Up-Regulation | 3 | 2004 | 740 | 0.250 |
Why?
|
| Mice, Knockout | 6 | 2012 | 2161 | 0.250 |
Why?
|
| I-kappa B Kinase | 3 | 2016 | 42 | 0.240 |
Why?
|
| Automation | 2 | 2024 | 115 | 0.240 |
Why?
|
| Aged | 20 | 2025 | 20973 | 0.240 |
Why?
|
| Adult | 23 | 2025 | 28725 | 0.240 |
Why?
|
| MAP Kinase Signaling System | 2 | 2003 | 206 | 0.230 |
Why?
|
| Inflammation | 3 | 2016 | 1068 | 0.220 |
Why?
|
| src-Family Kinases | 1 | 2004 | 70 | 0.220 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 1094 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 76 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 684 | 0.210 |
Why?
|
| Immunophenotyping | 1 | 2024 | 226 | 0.200 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2003 | 3 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3927 | 0.190 |
Why?
|
| Ovalbumin | 2 | 2014 | 110 | 0.190 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 102 | 0.180 |
Why?
|
| Interleukin-2 | 3 | 2011 | 248 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2025 | 9177 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2023 | 281 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 307 | 0.170 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1829 | 0.170 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 175 | 0.170 |
Why?
|
| Kinetics | 3 | 2018 | 1562 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1791 | 0.170 |
Why?
|
| Plasma | 1 | 2020 | 51 | 0.170 |
Why?
|
| Immunoassay | 1 | 2020 | 100 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 115 | 0.160 |
Why?
|
| Cells, Cultured | 6 | 2011 | 2940 | 0.160 |
Why?
|
| Immunotherapy | 5 | 2024 | 766 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 157 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 46 | 0.160 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 148 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 488 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 7230 | 0.160 |
Why?
|
| Prognosis | 4 | 2020 | 4030 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 644 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 238 | 0.150 |
Why?
|
| Biomarkers | 3 | 2021 | 1932 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 406 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 129 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 310 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 855 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 3157 | 0.140 |
Why?
|
| Graft Survival | 3 | 2016 | 942 | 0.130 |
Why?
|
| Male | 14 | 2025 | 45872 | 0.130 |
Why?
|
| Interferon-gamma | 2 | 2016 | 467 | 0.130 |
Why?
|
| Apoptosis | 3 | 2011 | 1760 | 0.130 |
Why?
|
| Isoenzymes | 2 | 2008 | 278 | 0.130 |
Why?
|
| Protein Kinase C | 2 | 2008 | 267 | 0.130 |
Why?
|
| Azetidines | 1 | 2017 | 37 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1973 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 382 | 0.130 |
Why?
|
| Prevalence | 1 | 2021 | 1349 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2020 | 705 | 0.130 |
Why?
|
| Neoplasms | 3 | 2024 | 3248 | 0.120 |
Why?
|
| Microfluidics | 1 | 2016 | 57 | 0.120 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 30 | 0.120 |
Why?
|
| Alleles | 1 | 2019 | 1157 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 72 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 162 | 0.120 |
Why?
|
| Piperidines | 1 | 2017 | 171 | 0.120 |
Why?
|
| Immune Tolerance | 3 | 2012 | 385 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2018 | 286 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1773 | 0.120 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 2086 | 0.120 |
Why?
|
| Cell Survival | 3 | 2014 | 1030 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2011 | 728 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 120 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 439 | 0.110 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 278 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2017 | 337 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1816 | 0.110 |
Why?
|
| Body Weight | 1 | 2016 | 460 | 0.110 |
Why?
|
| Drug Tolerance | 1 | 2014 | 64 | 0.110 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 31 | 0.110 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2014 | 9 | 0.110 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 30 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 2004 | 22 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 625 | 0.100 |
Why?
|
| Enteral Nutrition | 1 | 2014 | 105 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 1034 | 0.100 |
Why?
|
| Mice, Inbred C3H | 3 | 2012 | 372 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 163 | 0.100 |
Why?
|
| Antigens | 1 | 2014 | 231 | 0.100 |
Why?
|
| Heart | 1 | 2016 | 592 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2012 | 7 | 0.100 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 2 | 2009 | 8 | 0.090 |
Why?
|
| Cross-Priming | 1 | 2012 | 54 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 657 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 89 | 0.090 |
Why?
|
| beta Catenin | 1 | 2014 | 266 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2024 | 92 | 0.090 |
Why?
|
| Time Factors | 5 | 2019 | 5585 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2016 | 873 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2008 | 1755 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 1192 | 0.090 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 216 | 0.090 |
Why?
|
| Liquid Biopsy | 2 | 2022 | 48 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 1089 | 0.090 |
Why?
|
| Multiprotein Complexes | 2 | 2009 | 108 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 2494 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2012 | 260 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1798 | 0.090 |
Why?
|
| Colitis | 1 | 2014 | 262 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2006 | 133 | 0.080 |
Why?
|
| Microbiota | 1 | 2016 | 426 | 0.080 |
Why?
|
| Colon | 1 | 2014 | 541 | 0.080 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2010 | 37 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2778 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2011 | 188 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 667 | 0.080 |
Why?
|
| Peptides | 2 | 2011 | 672 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2009 | 207 | 0.080 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2012 | 247 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 825 | 0.080 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2009 | 7 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 589 | 0.080 |
Why?
|
| Mutation | 4 | 2023 | 4374 | 0.080 |
Why?
|
| Phenotype | 1 | 2016 | 2579 | 0.080 |
Why?
|
| Chromatin | 1 | 2012 | 450 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2009 | 50 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 54 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2025 | 1196 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 7025 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 349 | 0.070 |
Why?
|
| Survival Rate | 2 | 2025 | 1985 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 280 | 0.070 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2008 | 29 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2008 | 43 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2008 | 10 | 0.070 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 55 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2011 | 797 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 37 | 0.070 |
Why?
|
| Disease Progression | 3 | 2019 | 1564 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 270 | 0.070 |
Why?
|
| Epidermis | 1 | 2007 | 104 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 187 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2021 | 1546 | 0.060 |
Why?
|
| Adolescent | 4 | 2021 | 9895 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 367 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 69 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 101 | 0.060 |
Why?
|
| Stem Cells | 1 | 2008 | 394 | 0.060 |
Why?
|
| Lung Transplantation | 1 | 2010 | 367 | 0.060 |
Why?
|
| Glioma | 1 | 2008 | 321 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2019 | 10288 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 224 | 0.060 |
Why?
|
| Butadienes | 1 | 2004 | 34 | 0.060 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 35 | 0.060 |
Why?
|
| Superantigens | 1 | 2004 | 24 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2012 | 1730 | 0.050 |
Why?
|
| Nitriles | 1 | 2004 | 157 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2004 | 113 | 0.050 |
Why?
|
| Imidazoles | 1 | 2004 | 144 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2550 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2090 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 3110 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 212 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2040 | 0.050 |
Why?
|
| Sirolimus | 1 | 2004 | 177 | 0.050 |
Why?
|
| Calcineurin | 1 | 2003 | 19 | 0.050 |
Why?
|
| Gene Expression | 3 | 2016 | 1320 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 98 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 195 | 0.050 |
Why?
|
| Pyridines | 1 | 2004 | 319 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 290 | 0.050 |
Why?
|
| DNA Probes | 1 | 2002 | 77 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2002 | 59 | 0.050 |
Why?
|
| Eukaryotic Cells | 1 | 2002 | 44 | 0.050 |
Why?
|
| Ribose | 1 | 2022 | 20 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 63 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2023 | 145 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 59 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 64 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 382 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 398 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 897 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 286 | 0.040 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2020 | 4 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 303 | 0.040 |
Why?
|
| Blood Circulation | 1 | 2020 | 31 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2021 | 88 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 51 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 131 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 107 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 109 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 109 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 252 | 0.040 |
Why?
|
| Binding Sites | 2 | 2014 | 1167 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 331 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 297 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 313 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 156 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 30 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 304 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 271 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 713 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1220 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 10 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 196 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 60 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 81 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 99 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2011 | 75 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 131 | 0.040 |
Why?
|
| Protein Kinase C-theta | 2 | 2008 | 16 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 185 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 66 | 0.040 |
Why?
|
| Microscopy, Confocal | 2 | 2011 | 286 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 320 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 62 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 349 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 423 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 580 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 417 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 188 | 0.030 |
Why?
|
| Models, Biological | 1 | 2004 | 1810 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2018 | 180 | 0.030 |
Why?
|
| CD40 Ligand | 2 | 2008 | 77 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 367 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 857 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 555 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 53 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 79 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 285 | 0.030 |
Why?
|
| Transfection | 2 | 2011 | 908 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2008 | 482 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 558 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7768 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 145 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 117 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 173 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 175 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 207 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 218 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 901 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 322 | 0.030 |
Why?
|
| Smoking | 1 | 2018 | 653 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 165 | 0.030 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Genes, APC | 1 | 2014 | 27 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2014 | 80 | 0.030 |
Why?
|
| Sulfasalazine | 2 | 2004 | 33 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 548 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2014 | 82 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 380 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 769 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 299 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1981 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 103 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 688 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 909 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2016 | 298 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 481 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2004 | 522 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 1159 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 793 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 465 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 142 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 69 | 0.020 |
Why?
|
| Protein Binding | 2 | 2004 | 1560 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 847 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2883 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 143 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2008 | 10 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2008 | 73 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2008 | 55 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 34 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 797 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1267 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2008 | 145 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 54 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2008 | 144 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 411 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 233 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 306 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 204 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 284 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2006 | 48 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 692 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 830 | 0.020 |
Why?
|
| Ionomycin | 1 | 2006 | 21 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 20 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2006 | 37 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 35 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 48 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1808 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 145 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2006 | 281 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2006 | 171 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2006 | 151 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 996 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2008 | 447 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 216 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 42 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 563 | 0.010 |
Why?
|
| Dimerization | 1 | 2004 | 150 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 280 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2004 | 138 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 648 | 0.010 |
Why?
|
| Introns | 1 | 2004 | 304 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 526 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 12 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 2002 | 21 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2002 | 23 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2002 | 22 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 49 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2090 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 1375 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3040 | 0.010 |
Why?
|